GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Cyclically Adjusted FCF per Share

Repligen (Repligen) Cyclically Adjusted FCF per Share : $0.74 (As of Mar. 2024)


View and export this data going back to 1986. Start your Free Trial

What is Repligen Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Repligen's adjusted free cash flow per share for the three months ended in Mar. 2024 was $0.643. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $0.74 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Repligen's average Cyclically Adjusted FCF Growth Rate was 19.40% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 14.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 19.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 10.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Repligen was 146.60% per year. The lowest was -6.30% per year. And the median was 15.60% per year.

As of today (2024-05-21), Repligen's current stock price is $166.145. Repligen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was $0.74. Repligen's Cyclically Adjusted Price-to-FCF of today is 224.52.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Repligen was 621.65. The lowest was 44.35. And the median was 210.29.


Repligen Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Repligen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Cyclically Adjusted FCF per Share Chart

Repligen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.39 0.46 0.57 0.62 0.69

Repligen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.62 0.64 0.69 0.69 0.74

Competitive Comparison of Repligen's Cyclically Adjusted FCF per Share

For the Medical Instruments & Supplies subindustry, Repligen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Repligen's Cyclically Adjusted Price-to-FCF falls into.



Repligen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Repligen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.643/131.7762*131.7762
=0.643

Current CPI (Mar. 2024) = 131.7762.

Repligen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.051 100.560 0.067
201409 0.138 100.428 0.181
201412 -0.026 99.070 -0.035
201503 -0.107 99.621 -0.142
201506 0.206 100.684 0.270
201509 0.186 100.392 0.244
201512 0.083 99.792 0.110
201603 -0.127 100.470 -0.167
201606 0.281 101.688 0.364
201609 -0.094 101.861 -0.122
201612 0.032 101.863 0.041
201703 -0.004 102.862 -0.005
201706 0.041 103.349 0.052
201709 -0.064 104.136 -0.081
201712 0.303 104.011 0.384
201803 0.000 105.290 0.000
201806 0.069 106.317 0.086
201809 0.338 106.507 0.418
201812 0.002 105.998 0.002
201903 0.129 107.251 0.158
201906 0.255 108.070 0.311
201909 0.291 108.329 0.354
201912 0.199 108.420 0.242
202003 0.085 108.902 0.103
202006 0.230 108.767 0.279
202009 0.306 109.815 0.367
202012 0.057 109.897 0.068
202103 0.003 111.754 0.004
202106 0.360 114.631 0.414
202109 0.189 115.734 0.215
202112 0.281 117.630 0.315
202203 -0.087 121.301 -0.095
202206 0.344 125.017 0.363
202209 -0.282 125.227 -0.297
202212 0.710 125.222 0.747
202303 0.030 127.348 0.031
202306 0.441 128.729 0.451
202309 0.530 129.860 0.538
202312 0.322 129.419 0.328
202403 0.643 131.776 0.643

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Repligen  (NAS:RGEN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Repligen's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=166.145/0.74
=224.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Repligen was 621.65. The lowest was 44.35. And the median was 210.29.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Repligen Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Repligen's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Repligen (Repligen) Business Description

Traded in Other Exchanges
Address
41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
Executives
Christine Gebski officer: See Remarks C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot officer: President and CCO C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland officer: CFO 10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes director 579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres officer: CFO REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt director, officer: Chief Executive Officer 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel officer: Senior VP, R&D 41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund officer: SVP, Global Operations & IT C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov director C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton director C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr director
Nicolas Barthelemy director 1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox director C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre director C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453

Repligen (Repligen) Headlines